ArticleFrontiers in public health2025
Global, regional, and national epidemiology and risk factors of geriatric digestive system cancers from 1990 to 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Using Global Burden of Disease (GBD) 2021 data, we analyzed incidence, mortality, disability-adjusted life years (DALYs), and risk factors for six geriatric digestive system cancers (GDSC) in adults aged ≥60 years from 1990 to 2021; assessed Socio-demographic Index (SDI) impacts; and projected trends to 2050. Methods: The joinpoint regression model was used to analyze the age-standardized data for temporal trends; the decomposition method was used to assess the contributions of population growth, aging, and epidemiological changes; and frontier analysis was used to evaluate opportunities for burden reduction across countries. Results: Globally, the incidence of GDSC increased from 1,876,969 [age-standardized incidence rate (ASIR) 405.48/100,000] in 1990 to 3,854,209 (ASIR 360.89/100,000) in 2021, with a slight decrease in ASIR [-0.57% average annual percentage change (AAPC)]. From 1990 to 2021, global GDSC deaths rose to 2,856,742, but age-standardized mortality rate (ASMR) declined to 270.14, with an AAPC of -1.72%. Gastric cancer showed the largest decline in incidence (-2.21% AAPC), whereas liver cancer increased (0.74% AAPC). Gender disparities were evident, with higher rates in males. High-income Asia-Pacific and East Asia had the highest ASIR and ASMR. Decomposition analysis showed that population growth was the major factor in GDSC burden changes, especially in high-SDI regions. By 2050, ASIR and ASMR are expected to continue declining, particularly for esophageal and gastric cancers. Major risk factors include smoking, alcohol, diet, and metabolic factors such as high body mass index (BMI) and elevated fasting glucose. Conclusion: Despite an overall decline in GDSC burden, health disparities persist, particularly between high- and low-SDI regions. The study provides valuable insights into risk factors and projections for disease burden and offers guidance for targeted prevention efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.